Acipam 5 mg Tablet

Acipam 5 mg Tablet — Escitalopram 5mg (SSRI Antidepressant)

1. Indications & Clinical Uses

Acipam 5 contains escitalopram, the S-enantiomer of citalopram and the most selective SSRI currently available. Escitalopram is the most commonly prescribed antidepressant worldwide due to its excellent efficacy-tolerability balance, low drug interaction profile, and once-daily convenient dosing. The 5 mg tablet is specifically designed for initiation of therapy and for elderly patients or those with hepatic impairment who require lower starting doses.

Approved indications: Major Depressive Disorder (MDD) — first-line treatment; Generalised Anxiety Disorder (GAD) — first-line treatment; Panic Disorder (with or without agoraphobia); Social Anxiety Disorder (Social Phobia); Obsessive-Compulsive Disorder (OCD).

Diabetes connection: Depression affects 15–25% of people with diabetes — three times the rate in the general population. Diabetic depression is associated with poorer glycaemic control, reduced medication adherence, worse cardiovascular outcomes, and higher all-cause mortality. Escitalopram is the preferred SSRI for diabetic patients with depression because it has minimal effects on blood glucose, minimal drug interactions with diabetic medications, and does not cause the weight gain associated with some other antidepressants. Treating depression in diabetic patients with escitalopram has been shown to improve HbA1c, medication adherence, and quality of life.

2. Mechanism of Action

Escitalopram selectively and potently inhibits the serotonin transporter (SERT), blocking the reuptake of serotonin (5-HT) from the synaptic cleft back into the pre-synaptic neuron. This increases the concentration of serotonin available at postsynaptic receptors, gradually normalising serotonergic neurotransmission in limbic and cortical circuits involved in mood regulation, anxiety, and cognition.

Escitalopram's selectivity for SERT is approximately 100 times greater than its next most potent receptor interaction, explaining its clean side-effect profile compared to older antidepressants (TCAs, MAOIs) and even other SSRIs. Unlike citalopram (the racemic mixture), escitalopram eliminates the inactive R-enantiomer that contributes to side effects including QT prolongation, resulting in better efficacy at lower doses and improved tolerability.

Full antidepressant effect typically requires 2–4 weeks of consistent treatment as receptor adaptation and neuroplasticity changes develop. Early response (within 1–2 weeks) is often seen for anxiety and sleep, before full mood improvement occurs.

3. Dosage & Administration

Major Depression / GAD (adults):
Start: 10 mg once daily (may start at 5 mg once daily for first 1–2 weeks to minimise initial side effects).
Usual effective dose: 10–20 mg/day.
Maximum: 20 mg/day.
Take once daily in the morning or evening — consistent timing. Can be taken with or without food.

Elderly patients (≥65 years): Start with 5 mg once daily for at least 2 weeks before increasing to 10 mg if needed. Maximum dose in elderly: 10 mg/day.

Hepatic impairment: 5 mg once daily for 2 weeks, then carefully increased to 10 mg if needed.

Renal impairment: No dose adjustment needed for mild-moderate renal impairment. Use with caution in severe renal impairment (CrCl <30 ml/min).

Duration: Treat acute episode for minimum 6 months after remission. For recurrent depression: 2+ years of maintenance. Never stop abruptly — taper over 4–8 weeks to avoid discontinuation syndrome.

4. Side Effects

Common (≥10%): Nausea (most common, especially first 1–2 weeks, usually resolves), headache, dry mouth, insomnia or somnolence, increased sweating, sexual dysfunction (decreased libido, delayed orgasm/ejaculation) — affects 15–40% of patients and is the most common reason for discontinuation.

Common (1–10%): Diarrhoea, constipation, fatigue, dizziness, weight changes (modest — less than with paroxetine or mirtazapine), tremor, anxiety (paradoxical increase in anxiety may occur in first 1–2 weeks — transient).

Serious but uncommon: Serotonin syndrome (especially with other serotonergic agents — fever, agitation, tremor, diarrhoea, rapid heart rate); QT prolongation (dose-dependent; less than with citalopram but monitor ECG at >10 mg); hyponatraemia (SIADH — especially in elderly, typically in first 3 months); suicidal ideation increase (especially in patients <25 years — monitor closely during first 4 weeks of treatment); mania induction in undiagnosed bipolar disorder; bleeding risk (NSAIDs + escitalopram = higher GI bleed risk).

5. Contraindications

Contraindicated in: concurrent use of MAO inhibitors (selegiline, phenelzine, tranylcypromine) — allow 14-day washout; pimozide co-administration (QT risk); congenital long QT syndrome; hypersensitivity to escitalopram or citalopram; concurrent use with linezolid or IV methylene blue (serotonin syndrome risk).

6. Warnings & Precautions

Suicidality monitoring: Antidepressants increase the risk of suicidal thoughts and behaviour in children, adolescents, and young adults (≤25 years) during early treatment. Monitor closely during the first 4 weeks, especially when starting or changing doses. This risk is NOT present in adults ≥25 years and is reversed (protective) in adults ≥65 years.

Bipolar disorder: Screen for bipolar history before prescribing. SSRI monotherapy can precipitate mania in undiagnosed bipolar disorder.

Discontinuation syndrome: Never stop escitalopram abruptly. Symptoms include dizziness, flu-like symptoms, irritability, electric shock sensations ("brain zaps"), insomnia, and nausea. Always taper over 4–8 weeks.

Diabetic patients: Escitalopram may modestly affect blood glucose — monitor during initiation. The antidepressant effect itself improves medication adherence and HbA1c in depressed diabetic patients. Any initial blood glucose changes settle with continued treatment.

7. Drug Interactions

Major: MAO inhibitors — fatal serotonin syndrome (contraindicated, 14-day washout required). Pimozide — QT prolongation (contraindicated). Linezolid, methylene blue — serotonin syndrome.

Significant: Other serotonergic drugs (tramadol, triptans, St John's Wort, SNRIs, opioids) — serotonin syndrome risk; NSAIDs / aspirin / anticoagulants (warfarin) — increased bleeding risk; alcohol — potentiates CNS depression; QT-prolonging drugs — avoid combination; lithium — increased serotonergic effects; metoprolol — escitalopram inhibits CYP2D6 weakly, can mildly increase metoprolol levels.

Diabetic medications: No clinically significant interactions with metformin, insulin, sulfonylureas, or DPP-4 inhibitors at standard escitalopram doses. One of the reasons escitalopram is preferred over other antidepressants in diabetic patients.

8. Pharmacokinetics

Oral bioavailability: ~80%. Tmax: 4 hours. Protein binding: 56%. Volume of distribution: ~12 L/kg. Half-life: 27–32 hours — enables once-daily dosing with stable steady-state plasma levels achieved in ~7 days. Metabolism: hepatic via CYP2C19, CYP3A4, and CYP2D6. Weak inhibitor of CYP2D6 (low drug interaction potential). Renal excretion: ~8% unchanged. Steady-state achieved: 1 week. Not significantly affected by food.

9. Storage

Store below 30°C, away from light and moisture. Keep in original blister pack. Keep out of reach of children — escitalopram overdose in children is a medical emergency.

10. Missed Dose & Discontinuation

If a dose is missed and it is within 12 hours, take it immediately. If more than 12 hours have passed, skip it and take the next dose at the regular time. Never double dose. Never stop escitalopram suddenly — always discuss tapering with your doctor even if feeling better.

11. Overdose

Symptoms: nausea, vomiting, agitation, tremor, somnolence, serotonin syndrome features, QT prolongation, seizures, cardiac arrhythmias. There is no specific antidote. Supportive care: activated charcoal (if within 1 hour), cardiac monitoring (ECG), airway protection. Seek emergency care immediately.

12. Clinical Evidence

Escitalopram is consistently ranked as one of the most efficacious and best-tolerated antidepressants in network meta-analyses. The landmark Cipriani et al. (2018, The Lancet, n=116,477 patients) network meta-analysis — the largest antidepressant meta-analysis ever conducted — ranked escitalopram and sertraline highest for the combination of efficacy and acceptability. STAR*D: escitalopram achieved remission in 36% of treatment-naive MDD patients at 14 weeks. STEP-BD: escitalopram effective for bipolar depression adjunct treatment. For diabetic patients specifically: a 24-week RCT (Lustman 2006, Diabetes Care) found escitalopram significantly reduced depression scores AND improved medication adherence vs. placebo in T2DM patients with MDD.

13. Patient Counselling Points

• Onset: Antidepressant effects take 2–4 weeks to develop fully — do not stop because you don't feel better immediately.
• Never stop suddenly — always taper with doctor guidance to avoid discontinuation syndrome.
• Sexual side effects are common but manageable — discuss with doctor if troublesome (dose adjustment or switch possible).
• Avoid alcohol during treatment.
• Diabetic patients: Escitalopram will not significantly affect your blood sugar or interact with your diabetes medications.
• Report any worsening depression, unusual agitation, or thoughts of self-harm immediately to your doctor.
• Suicidal thoughts: If you experience increased thoughts of suicide or self-harm — especially in first 4 weeks — contact your doctor or emergency services immediately.

Frequently Asked Questions (FAQ)

Q1. How long does Acipam (Escitalopram) take to work?
Most patients notice early improvements in sleep, energy, and anxiety within 1–2 weeks of starting escitalopram. The full antidepressant effect on mood takes 4–6 weeks. Complete stabilisation of all symptoms may take 8–12 weeks. This delay occurs because antidepressants work by gradually remodelling serotonin receptor expression and promoting neuroplasticity in brain circuits involved in mood — these are slow biological processes. If no improvement is seen after 6–8 weeks at therapeutic dose, your doctor may adjust the dose or consider a different treatment.

Q2. Is Acipam (Escitalopram) safe for diabetic patients?
Escitalopram is generally considered the safest antidepressant for most diabetic patients. It has minimal interactions with metformin, insulin, sulfonylureas, and other common diabetic medications. It does not cause significant weight gain or worsen metabolic parameters. Importantly, treating depression with escitalopram in diabetic patients has been shown to improve HbA1c, medication adherence, and quality of life. Blood glucose should be monitored during the first few weeks of treatment as individual responses may vary.

Q3. What is the difference between Acipam 5mg and Acipam 10mg?
Acipam 5mg is the starting/low dose — used for initiation of therapy (especially in elderly patients, those with hepatic impairment, or those prone to side effects), and for dose stepping at the beginning of treatment. The therapeutic target dose for most adults is 10 mg/day, with some patients benefiting from 20 mg/day. Acipam 5mg allows gradual dose escalation that minimises initial side effects like nausea. Most adults will be started on 5–10 mg for the first 1–2 weeks then moved to 10 mg maintenance.

Q4. Can I stop taking Acipam when I feel better?
No — this is one of the most important things to understand about antidepressant treatment. Stopping escitalopram when you feel better is like stopping blood pressure medication when your blood pressure normalises — the drug is what's keeping you well. Guidelines recommend continuing antidepressants for at least 6–12 months after full remission (feeling completely back to normal) to prevent relapse. Stopping too early is the most common cause of relapse. When it is time to stop, always taper slowly over 4–8 weeks under doctor guidance — never stop abruptly.

⚕ Medical Disclaimer: Acipam is a prescription antidepressant — use only under the supervision of a registered physician or psychiatrist. If you or someone you know is having thoughts of suicide or self-harm, seek immediate emergency help. This content is for educational purposes only and does not replace professional medical advice.